Insiders Worth Watching: Fate Therapeutics Inc (NASDAQ:FATE) Chief Medical Officer Chris Storgard, Purchases $99997 in Stock

November 28, 2016 - By Peter Kolinski

Insiders Worth Watching: Fate Therapeutics Inc (NASDAQ:FATE) Chief Medical Officer Chris Storgard, Purchases $99997 in Stock

Chris Storgard Insider Buy

In an electronic document that’s filled with the Security and Exchange Commission, it was stated that the Chief Medical Officer of Fate Therapeutics Inc Chris Storgard, an insider in focus, made a deal for 37,593 shares of the public company, having a value near $99,997 US Dollars using an average market price per share of $2.7 US Dollars. Chris Storgard right now holds 46,683 shares or 0.14% of Fate Therapeutics Inc’s market cap.

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $8 is the highest target while $4 is the lowest. The $6.75 average target is 120.59% above today’s ($3.06) stock price. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. Raymond James initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Tuesday, October 6. Raymond James has “Outperform” rating and $8 price target. The firm has “Outperform” rating by Wedbush given on Tuesday, November 8. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Outperform” rating given on Friday, December 4 by Wells Fargo. The stock of Fate Therapeutics Inc (NASDAQ:FATE) has “Buy” rating given on Thursday, September 22 by Roth Capital. The rating was initiated by BMO Capital Markets with “Outperform” on Tuesday, April 12. The rating was initiated by TH Capital with “Buy” on Thursday, September 22.

Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.26, from 0.56 in 2016Q1. The ratio is positive, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.

Tocqueville Asset Mgmt L P holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 22,000 shares. Belmont Advisors holds 400,000 shares or 0.65% of its portfolio. The California-based Board Of Trustees Of The Leland Stanford Junior University has invested 0.07% in Fate Therapeutics Inc (NASDAQ:FATE). Polaris Venture Mgmt V Limited Liability Co last reported 4.51% of its portfolio in the stock. Redmile Group Ltd last reported 1.50 million shares in the company. Lombard Odier Asset Management (Usa) reported 256,426 shares or 0.05% of all its holdings. Blackrock Inv Mngmt Limited Liability Com has 0% invested in the company for 4,327 shares. Blackrock Fund Advisors holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 75,572 shares. Kingdon Management Limited Com accumulated 0.21% or 2.26 million shares. Renaissance Techs Ltd accumulated 180,700 shares or 0% of the stock. The New Jersey-based Jacobs Levy Equity Mgmt has invested 0.01% in Fate Therapeutics Inc (NASDAQ:FATE). Manufacturers Life Com The holds 184 shares or 0% of its portfolio. National Bank Of Mellon Corporation last reported 0% of its portfolio in the stock. Geode Ltd Limited Liability Company has invested 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). The California-based Franklin has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE).

About 213,335 shares traded hands or 12.52% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 60.61% since April 25, 2016 and is uptrending. It has outperformed by 54.59% the S&P500.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $101.13 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”

Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on March, 2. They expect $-0.29 EPS, down 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.27 actual EPS reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

Another recent and important Fate Therapeutics Inc (NASDAQ:FATE) news was published by Medgadget.com which published an article titled: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment ..” on September 14, 2016.

FATE Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>